Table 3 KEGG Enrichment Analysis of miR-583 and miR-877-5p target genes
KEGG ID | Pathway | Genes | P.value | FDR |
|---|---|---|---|---|
hsa04144 | Endocytosis | SMAD2, TFRC, CLTC, CBL, IGF1R, PLD2, CDC42, TRAF6, MVB12B, STAMBP, EPS15, VPS36, RAB11FIP4 | 3.61E-10 | 5.3E–l8 |
hsa05200 | Pathways in cancer | CDC42, SMAD2, GSK3B, CDKN1B, FZD5, TRAF6, KIT, CBL, SOS2, IGF1R, PLD2 | 6.83E-05 | 5.1E–3 |
hsa05205 | Proteoglycans in cancer | CDC42, SMAD2, FZD5, PLCE1, CBL, SOS2, IGF1R | 2.43E-04 | 4.1E–9 |
hsa04014 | Ras signaling pathway | CDC42, KIT, PLCE1, SOS2, IGF1R, PLD2 | 0.003458371 | 4.1E–5 |
hsa05224 | Breast cancer | GSK3B, FZD5, KIT, SOS2, IGF1R | 0.00381176 | 4.1E–1 |
hsa05226 | Gastric cancer | SMAD2, GSK3B, CDKN1B, FZD5, SOS2 | 0.004000612 | 3.1E–8 |
hsa04150 | mTOR signaling pathway | GSK3B, FZD5, SLC38A9, SOS2, IGF1R | 0.004711629 | 2.1E–9 |
hsa04012 | ErbB signaling pathway | GSK3B, CDKN1B, CBL, SOS2 | 0.006087197 | 2.1E–2 |
hsa05225 | Hepatocellular carcinoma | SMAD2, GSK3B, FZD5, SOS2, IGF1R | 0.006121151 | 1.1E–5 |
hsa05215 | Prostate cancer | GSK3B, CDKN1B, SOS2, IGF1R | 0.008764397 | 0.00084 |